An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy

Trial Profile

An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use
  • Acronyms PANEX
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top